← Back to Trade Analysis Quick Facts
| Metric | Value |
|---|
| US Import Rank | #9 |
| 2024 Import Value | ~$104 billion |
| % of US Imports | 3.1% |
| 2024 Tariff Rate | ~1% average |
| Current Tariff Rate | 15% (EU framework) |
| Trade Agreement | EU-US Framework Agreement |
| US Trade Balance | -$86.7 billion deficit |
Trade Agreement
EU-US Framework Agreement
Status: Ireland trades as EU member state
Key Terms:
- 15% ceiling on most goods
- Sector-specific exemptions
- Same terms as Germany, France, Italy
Note: Ireland has no bilateral agreement with the US; all trade governed by EU-US relations.
Ireland’s Unique Trade Profile
Why Ireland Has a Large Trade Deficit
Ireland’s large trade deficit with the US ($86.7B) reflects:
| Factor | Explanation |
|---|
| Pharma headquarters | Major drug companies based in Ireland |
| Tax optimization | Corporate structures route sales through Ireland |
| IP holding | Intellectual property held in Irish subsidiaries |
| Medical devices | Manufacturing hub |
The “Leprechaun Economics” Factor
Ireland’s trade statistics are inflated by multinational corporate structures:
- Pfizer, Johnson & Johnson, Abbott, Medtronic have major Irish operations
- Sales often recorded in Ireland for tax purposes
- Actual physical exports may be lower than statistics suggest
2024 Baseline Tariff Structure
| Product Category | 2024 Rate | Notes |
|---|
| Most goods | ~1% | Low EU MFN rates |
| Pharmaceuticals | Near 0% | Critical products |
| Medical devices | Low | Important sector |
| Steel | 25% | Section 232 |
2025 Tariff Changes
Timeline (Same as EU)
Apr 2, 2025 "Liberation Day" - 20% reciprocal tariff on EU
Apr 9, 2025 90-day pause, reduced to 10%
Jul 27, 2025 US-EU deal: 15% rate agreed
Aug 21, 2025 Framework agreement signed
Jan 2026 Greenland crisis: additional tariffs threatened
Current Tariff Structure (January 2026)
| Product Category | Current Rate | Notes |
|---|
| General goods | 15% | EU framework |
| Generic pharmaceuticals | 0% | Exempt |
| Aircraft/parts | 0% | Exempt |
| Steel | 50% | Section 232 |
| Aluminum | 50% | Section 232 |
Exemptions
Pharmaceutical Exemption
Critical for Ireland: 84% of drugs are exempted
| Product Type | Status |
|---|
| Generic drugs | Exempt (0%) |
| Branded drugs | 15% |
| Medical devices | 15% |
Aircraft and Parts
| Product | Status |
|---|
| Aircraft | Exempt (0%) |
| Components | Exempt (0%) |
| Engines | Exempt (0%) |
Economic Effects
Projected Impact
| Scenario | GDP Impact |
|---|
| 25% tariff + EU retaliation | -3.7% |
| Current 15% framework | Less severe |
Potential Losses
| Category | Amount |
|---|
| Trade at risk | €18.4 billion |
| Corporation tax at risk | €15 billion |
Pre-Tariff Front-Loading
| Metric | Change (Jan-Sept 2025) |
|---|
| Manufacturing exports to US | Up 90% |
| Reason | Companies shipping before tariffs hit |
Key Products Affected
Pharmaceuticals (€33 billion - 40% to US)
| Company | Irish Operations |
|---|
| Pfizer | Major manufacturing |
| Johnson & Johnson | Significant presence |
| Abbott | Key facilities |
| Merck | Irish operations |
| Bristol-Myers Squibb | Manufacturing |
Status: Generics exempt; branded at 15%
Medical Devices (€8 billion - 40% to US)
| Company | Products |
|---|
| Medtronic | Heart devices, diabetes care |
| Boston Scientific | Medical equipment |
| Stryker | Surgical equipment |
| Abbott | Diagnostics |
Tariff: 15%
Technology
| Product | Status |
|---|
| Software | Subject to tariffs |
| Hardware | Subject to tariffs |
| Semiconductors | Mixed |
Ireland’s Vulnerabilities
Concentration Risk
| Sector | Share of Exports to US |
|---|
| Pharmaceuticals | ~40% |
| Medical devices | ~40% |
| Technology | Significant |
Tax Revenue Concerns
| Risk | Detail |
|---|
| Corporation tax | €15B “at risk” |
| Multinationals | May restructure |
| Employment | Pharma/tech jobs vulnerable |
Small Open Economy
Ireland is highly exposed to trade disruption:
- Exports = 137% of GDP (including re-exports)
- US is largest non-EU trade partner
- Limited ability to influence EU negotiating position
Greenland Crisis Impact (January 2026)
Background
Trump’s Greenland acquisition push affected EU relations:
- Additional tariffs threatened on EU countries
- Ireland among potential targets
- Framework agreement implementation uncertain
Ireland’s Position
| Stance | Detail |
|---|
| Within EU | Must follow EU common position |
| Bilateral | Limited direct leverage |
| US relationship | Strong historical ties |
| Business community | Advocating calm approach |
US-Ireland Special Relationship
Historical and Cultural Ties
| Factor | Relevance |
|---|
| Irish-American population | ~32 million claim Irish ancestry |
| Political influence | Irish-American lobby |
| FDI relationship | Deep economic ties |
| Cultural connection | St. Patrick’s Day, etc. |
Foreign Direct Investment
| Direction | Amount |
|---|
| US FDI in Ireland | ~$500 billion |
| Irish FDI in US | ~$400 billion |
| Jobs in Ireland (US companies) | ~190,000 |
| Jobs in US (Irish companies) | ~100,000 |
Significant Events
| Date | Event | Impact |
|---|
| Apr 2, 2025 | EU tariffs announced | 20% on Ireland |
| Apr 9, 2025 | 90-day pause | Relief at 10% |
| Jul 27, 2025 | EU deal | 15% agreed |
| Jan-Sept 2025 | Front-loading | 90% export surge |
| Jan 2026 | Greenland crisis | New uncertainty |
Current Status (January 2026)
What’s in Effect
- 15% tariff on most goods (EU framework)
- 0% on generic pharma and aircraft
- 50% on steel/aluminum
Critical Protections
- 84% of pharma exports exempt
- Medical devices at 15% (manageable)
- Aircraft sector protected
Outstanding Issues
- Greenland crisis threatens escalation
- Branded pharma at 15%
- Long-term corporate structure risks
- €15B tax revenue concerns
Outlook
Ireland benefits from the pharmaceutical exemption, which protects its largest export sector. The 15% rate on other goods is manageable but represents a significant increase from pre-2025 levels. Ireland’s vulnerability lies in its concentrated export profile and dependence on multinational corporate structures that could be disrupted by prolonged trade tensions.
Sources